The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically significant (P-value = 0.0005), which exceeded the pre-specified success criterion. Leuprolide...
Hence then, the article about foresee pharmaceuticals announces the casppian phase 3 study meets primary efficacy endpoint demonstrating robust lh suppression with 6 month dosing interval of leuprolide mesylate was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate )
Also on site :
- Masonite International Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOOR
- For Iran’s Rulers, Refusing U.S. Demands Is a Risk Worth Taking
- Mexico fears more violence as tourists warned and schools closed following killing of powerful Cartel boss